IEXIdex Corporation
Earnings Recap
• Reported GAAP EPS of $1.61 up 27.78% YoY • Reported revenue of $886.9M up 8.92% YoY • IDEX Corporation is raising its full-year organic sales growth projection to 3% to 4% and adjusted diluted EPS guidance to $8.35 to $8.55, up from prior ranges, reflecting continued momentum.
Bullish
IDEX Corporation achieved strong sales and record orders, with reported diluted EPS increasing 28% and adjusted diluted EPS up 14%, leading to raised full-year guidance, driven by Health & Science Technologies segment growth.
Bearish
IDEX Corporation experienced gross margin compression due to unfavorable mix and price/cost pressures. Additionally, cash flows from operating activities decreased, reflecting higher capital expenditures and mixed segment organic sales performance.